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Abstract Background: The safety and effectiveness of lacosamide, an antiepileptic drug
(AED) that selectively enhances the slow inactivation of voltage-gated so-
dium channels without affecting rapid inactivation, has been demonstrated in
randomized, double-blind, placebo-controlled trials in adults with focal epi-
leptic seizures. Although lacosamide is approved for use in patients over 16
years of age, limited clinical experience exists for younger patients.
Objective: To assess the efficacy and tolerability of lacosamide in children
with refractory epilepsy.
Design/Methods: The trial was a prospective, open-label, observational,
multicenter study. A total of 130 patients aged less than 16 years (range 6
months to 16 years) with refractory epilepsy who had initiated treatment with
lacosamide were enrolled at 18 neuropediatric units in hospitals across Spain.
Patients with a variety of etiologies were enrolled, including those with partial
epilepsies and symptomatic, generalized epilepsy syndromes. Lacosamide
(VIMPAT; UCB Pharma SA, Brussels, Belgium) was primarily administered
once every 12 hours as an oral solution or as an oral tablet, with an initial dose
of 1–2mg/kg/day in the majority of cases. The majority of patients were also
receiving stable concomitant therapy with ‡1 other AED. Treatment response
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to lacosamide was determined by assessing the change in seizure frequency
after 3 months of lacosamide therapy. Responders were defined as patients
who achieved a seizure frequency reduction of >50%. Tolerability was assessed by
the reporting of adverse effects, laboratory testing, and electroencephalography
recordings.
Results: Lacosamide was dosed at a mean of 6.80 – 2.39mg/kg/day. After
3 months of lacosamide therapy, 62.3% of patients achieved a >50% reduc-
tion in seizure frequency, with complete seizure suppression being reported in
13.8% of patients. Adverse effects occurred in 39 patients (30%), but no dose-
response relationship was observed in terms of these events. In ten patients,
instability, difficulty walking, an inability to relate to subjective elements, and
blurred vision or dizziness were reported. A total of 13 patients discontinued
treatment – in five of these patients, symptom intensity remained unchanged
despite dose reduction, which led to treatment discontinuation. The symp-
toms were markedly different in each patient, preventing determination of a
causal factor(s).
Conclusions: The results of this study provide preliminary evidence for the
efficacy of lacosamide in children with refractory epilepsy. Further evalu-
ation in a randomized, controlled trial is needed to validate the efficacy in this
population and to fully investigate the adverse effects described here. We
recommend an initial dose of 1–2mg/kg/day, uptitrated to 6–9mg/kg/day
over 4–6 weeks.
Introduction
The antiepileptic drug (AED) lacosamide is
chemically composed of acetamido-N-benzyl-3-
methoxypropionamide, an amino acid with a
molecular weight of 250.3 g/mol, and is highly
soluble in water (25mg/mL).[1-4] The mechanism
of action through which lacosamide exerts its
antiepileptic effect is unique in that it selectively
enhances slow inactivation of voltage-gated sodium
channels without affecting rapid inactivation.[1-4]
This reduces the long-term availability of these
sodium channels, which results in diminished
pathological hyper-excitability without compromis-
ing physiological activity.[1-4] Therefore, lacosamide
does not completely block voltage-gated sodium
channels but, rather, acts as a modulator of these
channels.[1-4]
With regard to pharmacokinetics, lacosamide
has oral bioavailability of approximately 100%
and a very low plasma protein binding rate (<15%);
95% is excreted in urine, 40% as unaltered lacosa-
mide and 30% as inactive O-desmethyl metabo-
lite.[2-6] The maximum plasma drug concentration
(Cmax) is reached between 1 and 2 hours following
oral administration, with an elimination half-life
(t½) of 13 hours, thereby enabling administration
of two doses per day.[2-6] No pharmacokinetic in-
teractions have been observed in various clinical
trials with other AEDs, digoxin, metformin, ome-
prazole, or oral contraceptives containing ethinyl-
estradiol and levonorgestrel.[2-6]
The effectiveness and safety of lacosamide have
been demonstrated in three randomized, double-
blind, placebo-controlled clinical trials conducted
in adult patients with focal epileptic seizures. Al-
though lacosamide is approved for use in patients
over 16 years of age,[6-8] limited clinical experience
exists for younger patients.[9,10] Therefore, our
study was conducted to evaluate the efficacy and
tolerability of lacosamide in children aged less than
16 years with refractory epilepsy.
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Methods
Study Design
This was a prospective, open-label, observa-
tional, multicenter study conducted at 18 neuro-
pediatric units across Spain (listed in the Appen-
dix). Patients were recruited by neuropediatric
doctors at each participating unit over a period of
12 months, and were eligible for the study if they
had already initiated treatment with lacosamide
after a lack of response to prior antiepileptic treat-
ment, defined as a minimum of 2 months without
a clinical response to previously administered
AEDs. Lacosamide had been prescribed because
the neuropediatric doctor believed the patient
could benefit from its use. Patients were required
to have previously been treated with at least two
AEDs, to be less than 16 years of age, and to have
a diagnosis of refractory epilepsy that met the
current International League Against Epilepsy
(ILAE) criteria for refractory or difficult-to-control
epilepsy.[11] Patients with any neurodegenerative
diseases were excluded. Written informed consent
was obtained from the parents of children under
16 years of age, conforming to the recommend-
ations of the Declaration of Helsinki. The in-
formed consent document stated that the Sum-
mary of Product Characteristics for lacosamide
clearly indicates the use of the drug from the age
of 16 years and highlighted the potential side ef-
fects that should be monitored with special at-
tention. The manufacturer of lacosamide (UCB
Pharma) had no involvement in the study.
Lacosamide (VIMPAT; UCB Pharma SA,
Brussels, Belgium) was primarily used as an oral
solution (15mg/1 cc) or tablets (50mg, 100mg,
150mg, and 200mg), administered once every
12 hours. The initial dose ranged from 1 to
2mg/kg/day in the majority of cases (89.2%).
Patients were uptitrated from 1 or 2mg/kg/day to
6–9mg/kg/day over 4–6 weeks. Lacosamide was
acquired by the patients from pharmacies through
the Spanish National Health prescription service.
Concomitant AEDs (co-AEDs) were maintained
at a stable dose during the study. Treatment did
not exceed 6 months if there was an increase in
seizure frequency, if the onset of adverse effects
resulted in treatment withdrawal, or if the clinical
situation did not improve and the medication was
discontinued. Two-thirds of patients (66%) had
been on treatment for 6 months or more when the
data were collected. In cases where co-AEDs was
used, they were the same drugs the patients had
been taking prior to initiation of lacosamide.
Evaluations and Outcome Measures
Before lacosamide treatment was started, the
clinical status of patients was monitored by the
participating neuropediatric doctors every 6months,
with laboratory and electroencephalography (EEG)
assessments being conducted if deemed clinically
necessary. Patients were then followed up and
monitored by these participating doctors accord-
ing to a protocol established by general consensus
at the start of the study, with clinical and labor-
atory assessments completed quarterly.
Response to treatment was evaluated by the
difference between the number of epileptic seiz-
ures occurring during lacosamide treatment and
the number of epileptic seizures occurring in the
period prior to starting treatment with lacosa-
mide. The number of seizures was provided by
the patients’ parents, who completed a ‘seizure
calendar’. The seizure calendar was delivered to
parents at the start of treatment with lacosamide,
and thereafter they would fill it in. Prior to starting
lacosamide treatment, some (but not all) patients
had been creating and filling in their own seizure
calendar. After the start of lacosamide treatment,
however, all of them filled in this calendar.
Seizure frequency was measured during the
3-month period prior to lacosamide therapy and
after 3 months of lacosamide therapy. The main
efficacy outcome measure was the proportion of
responders to lacosamide therapy after 3 months
of treatment, which was defined as a reduction in
seizure frequency of >50%. Complete control was
defined as no seizures occurring in the analyzed
period. Patients were divided into five categories
according to the level of their response to treat-
ment: complete seizure control (group A); a re-
duction in seizure frequency of >75% (group B);
a reduction in seizure frequency of >50% to
75% (group C); no change in seizure frequency
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(group D); or an increase in seizure frequency
(group E).
Tolerability was assessed by the recording of
adverse effects and the attitudes adopted toward
transient initial symptoms, a reduction in the dose
of lacosamide or other AEDs, and lacosamide
withdrawal. Usually the parents/family of the pa-
tient reported adverse effects unless the patient was
capable of providing this information him- or her-
self, in which case reporting of adverse effects was
done by the patient and their parents/family. Con-
ventional laboratory tests (complete blood count,
transaminasemia, amylasemia, blood glucose, cre-
atininemia, cholesterolemia, and triglyceridemia)
and EEG recordings were also performed.
Statistical Analysis
The analysis of the mean lacosamide dosage
(in mg/kg/day) according to the percentage con-
trol of seizures (level of response) was performed
using the Kruskal-Wallis test. The association of
AEDs with different levels of response was ana-
lyzed by the w2 test. The analysis of the mean la-
cosamide dosage (in mg/kg/day) in patients with
and without adverse effects was performed using
the Mann-Whitney test.
Results
Clinical Characteristics and Disposition of
Subjects
Data on patient demographics and clinical
characteristics are summarized in table I. Overall,
130 cases of refractory epilepsy were analyzed
in patients under 16 years of age (mean age
8.01 – 4.25 years; range 6 months to 16 years).
Epilepsies of a symptomatic origin were due to
perinatal pathology (25.9%), malformations of
cortical development [MCD] (19.7%), other cer-
ebral malformations (14.8%), neuroectodermal
disorders (12.3%), central nervous system infec-
tions (8.6%), metabolic diseases (6.1%), genetic
alterations (4.9%), mesial sclerosis (3.7%), cere-
brovascular disease (2.4%), and presumed auto-
Table II. Concomitant antiepileptic drugs used with lacosamide in
patients with complete seizure control (group A; N = 21)











a 21 patients had complete control of seizures, but 3 discontinued
the treatment because of adverse effects.
b The numbers in brackets refer to patients in whom lacosamide
treatment was suspended.
co-AED = concomitant antiepileptic drug.
Table I. Characteristics of patients enrolled in the study (N =130)
Characteristic Value
Male sex (n [%]) 72 [55.4]
Age (years)
Mean – standard deviation 8.01 –4.25
Range 0.5–16
Etiology (n [%])
Symptomatic origin 82 [63.1]
Presumed symptomatic origin 36 [27.7]
Idiopathic origin 12 [9.2]
>20 seizures per month (n [%]) 70 [53.8]
Type of focal seizure (n [%])
Simple 32 [24.6]
Complex 93 [71.5]
Secondarily generalized 84 [64.6]
Use of co-AEDs (n [%])a
1 co-AED 41 [31.5]
2 co-AEDs 68 [52.3]
3 co-AEDs 17 [13.1]
>3 co-AEDs 3 [2.3]







a One patient reverted to monotherapy after a trial of combination
therapy and is therefore not included in this list.
co-AED = concomitant antiepileptic drug.
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immune disease [Rasmussen’s syndrome] (2.4%).
A high percentage of patients (81.5%) had cog-
nitive problems, of whom 56 (43%) had serious
retardation. The epileptic syndrome was identi-
fied in 26 cases, which included West syndrome
(eight cases); Dravet syndrome (six cases); con-
tinuous spike-wave during slow sleep syndrome
[CSWS] (five cases); Lennox syndrome, autoso-
mal dominant nocturnal frontal lobe epilepsy, or
Rasmussen’s syndrome (two cases each); and
Dulac devastating epilepsy (one case).
Lacosamide therapy was primarily used as an
oral solution (70.7%) or as a tablet; lacosamide
was also initiated parenterally in three patients.
The initial dose ranged from 1 to 2mg/kg/day in
the majority of cases (89.2%), with the final dose
being reached by 4 weeks in 45.3% of patients and
by 12 weeks in 33.7% of patients; 20.7% reached
the final dose in less than 4 weeks. The final mean
dose was 6.80 – 2.39mg/kg/day. Co-AEDs used
in conjunction with lacosamide during the study
included valproate (45.4% of patients), levetir-
acetam (39.2%), zonisamide (17.7%), oxcarbaze-
pine (13.8%), clobazam (13.8%), and topiramate
(13.1%).
Efficacy Outcomes
A total of 86 patients responded to lacosamide
therapy (66.2%), although five patients were not
classified as responders, because of poor toler-
ability that resulted in lacosamide withdrawal.
Therefore, a total of 81 responders (62.3%) were
identified who made up the first three groups
from the five categories, on the basis of their level
of response to lacosamide therapy.
Group A: A total of 21 patients (16.2%) had
complete control of seizures (seizure suppression),
although three patients experienced adverse effects
that impeded the continuation of treatment. There-
fore, complete control was observed in 18 patients
(13.8%), in whom a mean lacosamide dose of
6.97– 2.15mg/kg/day (range 4.61–13mg/kg/day)
was used. Among patients receiving mono- or
bi-/polytherapy, levetiracetam (9 out of 18 cases;
50%) and valproate (10 out of 18 cases; 55.5%)
were the two most commonly used co-AEDs in
this group (table II). Etiology and types of seizure
in group A are listed in table III; in the sympto-
matic group, one case of mitochondrial disease
and three cases of MCD were reported.
Group B:Overall, 33 patients (25.4%) achieved
a >75% reduction in seizure frequency, although
poor tolerability led to drug withdrawal in two
of these patients. Consequently, 31 patients
(23.8%) maintained this response level at a mean
lacosamide dose of 6.40 – 2.48mg/kg/day (range
2.14–13mg/kg/day). Among patients receiving
mono- or bi-/polytherapy, lacosamide was used
concomitantly with levetiracetam in 11 patients
(32.3%) and with valproate in 14 patients (43.7%)
Table IV. Concomitant antiepileptic drugs used with lacosamide in
patients with seizure frequency control of >75% (group B; n= 33)












a The number in brackets refers to a case in whom lacosamide
treatment was suspended.
co-AED = concomitant antiepileptic drug.
Table III. Etiology and types of seizure in patients with complete
seizure control (group A; N = 21)
Etiology Type of seizure Patients (n)
Idiopathic S+C 1
C 1





Presumably symptomatic G 1
C 3
C +2aG 2
2aG= secondarily generalized seizure; C = complex focal seizure;
G =generalized seizure; S = simple focal seizure.
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[table IV]. Etiology and types of seizure in group
B are listed in table V; in the symptomatic group,
five cases of MCD were observed, but no cases of
mitochondrial disease were reported.
GroupC:A seizure frequency reduction of >50%
to 75% was seen in 32 patients (24.6%), with a
mean lacosamide dose of 6.63 – 2.33mg/kg/day
(range 2.4–14.3mg/kg/day). Among patients re-
ceiving mono- or bi-/polytherapy, lacosamide
was used concomitantlywith levetiracetam in 13 pa-
tients (40.6%), with valproate in 13 patients (40.6%),
and with zonisamide in seven patients (21.8%)
[table VI]. Etiology and types of seizure in group
C are listed in table VII; in the symptomatic
group, three cases of mitochondrial disease and
four cases of MCD were observed.
Group D: No change in seizure frequency was
observed in 39 patients (30%), who received an
average dose of 7.26 – 2.62mg/kg/day (range
5–20mg/kg/day). The co-AEDs that were used
most often in groups A, B, and C were used less
frequently in group D. Among patients receiving
mono- or bi-/polytherapy, lacosamide was used
concomitantly with levetiracetam in 16 patients
(41%), with valproate in 21 patients (53.8%), and
with topiramate in 12 patients (30.8%) [table
VIII]. Etiology and types of seizure in group D
are listed in table IX; in the symptomatic group,
mitochondrial disease and MCD were observed
in one and four cases, respectively.
Group E: An increase in seizure frequency was
seen in five patients (3.8%). The mean lacosamide
dose in this group was 6.16– 0.52mg/kg/day (range
5.6–7mg/kg/day). Lacosamide was not used con-
comitantly with levetiracetam or valproate in these
patients, and no patients were receiving three or
more co-AEDs (table X). Etiology and types of
seizure in group E are listed in table XI; in the
symptomatic group, one case ofMCDwas reported.
Figure 1 shows the pattern of the treatment res-
ponse in this population of children with refractory
epilepsy. No statistically significant differences in
the mean lacosamide doses were seen between the
different groups (p = 0.499; Kruskal-Wallis test).
However, the mean lacosamide doses tended to
be similar in groups A, B, and C, but higher in
group D, with the aim of increasing the ther-
apeutic response.
No relationship between the response to lacosa-
mide therapy and epileptic syndrome was observed.
Two patients with Lennox-Gastaut syndrome re-
ported a focal seizure reduction of >50%. One pa-
tient with continuous partial epilepsy (Rasmussen’s
syndrome) appeared to achieve control of seizures
with lacosamide therapy.
Safety and Tolerability (Unfavorable and
Favorable Secondary Effects)
Adverse effects were reported by patients and
their families in 39 cases (30%) following treat-
ment with lacosamide. In 16 of these cases, the
Table VI. Concomitant antiepileptic drugs used with lacosamide in
patients with seizure frequency control of >50% (group C; N = 32)
















co-AED = concomitant antiepileptic drug.
Table V. Etiology and types of seizure in patients with seizure fre-
quency control of >75% (group B; N = 33)





S+C + 2aG 5
Presumably symptomatic C 7
S+C 2
S+C + 2aG 1
2aG= secondarily generalized seizure; C = complex focal seizure;
S= simple focal seizure.
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effects were initial and transient; in four cases, the
effects were tolerated without requiring dose
modification; in six cases, the effects disappeared
or were tolerated by lowering the lacosamide
dose; and in 13 cases, the effects required cessa-
tion of lacosamide. The mean dose of lacosamide
in the 39 patients who experienced an adverse
effect was 7.11 – 3.10mg/kg/day, compared with
6.56 – 2.21mg/kg/day in the 91 patients who did
not experience any adverse effects; no statistically
significant difference was seen between these two
doses (p = 0.304; Mann-Whitney test).
No cardiovascular effects were observed in our
patients. There were also no alterations in con-
ventional laboratory tests (complete blood count,
transaminasemia, amylasemia, blood glucose,
creatininemia, cholesterolemia, and triglyceridemia),
and no significant changes in EEG records.
Themost prevalent adverse effects were nausea
and vomiting (13 cases), instability (ten cases),
dizziness (five cases), nystagmus (three cases),
somnolence (three cases), weakness (two cases),
and adynamia (two cases). Anorexia, disorientation,
asthenia, headache, insomnia, irritability, attention
deficit, agitation, drop in academic achievement,
psychotic reaction, vision impairment, neck stiffness,
tonic upgaze, sialorrhea, and focal epileptic status
were much less common effects (one case each).
In ten patients, striking symptoms were ob-
served, including instability, difficulty walking, an
inability to relate subjective elements, and blurred
vision or dizziness. In five cases, symptom intensity
remained unchanged, despite an immediate dose
decrease, which eventually led to discontinuation
of treatment. In all cases, symptoms peaked with
the Cmax occurring between 2 and 5 hours after
drug administration, with no direct relationship to
the dose, speed of dose adjustment, or use of co-
AEDs. Adverse effects resulting in discontinuation
of lacosamide are detailed in table XII.
A significant improvement in behavior and
the speed of response to stimuli was reported by
the parents of 17 patients (13.0%) in groups A
and B, which may have been related to the use of
lacosamide.
Discussion
The results of this open-label study suggest
that lacosamide therapy may be an effective
treatment option in children with refractory epi-
lepsy. The epilepsy diagnosis criteria used in our
study were the same as those used in two previous
studies evaluating lacosamide therapy in chil-
dren.[9,10] In our study, a much larger sample of
patients was enrolled and a more favorable res-
ponse was observed, compared with the studies
conducted by Gavatha et al.[10] and Chez et al.[9]
Table VIII. Concomitant antiepileptic drugs used with lacosamide in
patients with no change in seizure frequency (group D; N = 39)

















co-AED = concomitant antiepileptic drug.
Table VII. Etiology and types of seizure in patients with seizure
frequency control of >50% (group C; N = 32)







S+C + 2aG 3
Presumably symptomatic C 3
S+C 1
C +2aG 7
2aG= secondarily generalized seizure; C = complex focal seizure;
S= simple focal seizure.
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We reported seizure suppression in 16.2% of
patients, compared with 11.1% in the study con-
ducted by Gavatha et al.[10] and 4.3% in the study
conducted by Chez et al.[9] The favorable res-
ponse in our study may have been a reflection of
the higher lacosamide doses that were used (a
mean dose 6.8mg/kg/day), compared with those
used by Gavatha et al.[10] (5.17mg/kg/day) and
Chez et al.[9] (3.6mg/kg/day).
Our results are suggestive of greater efficacy
with the combination of lacosamide and an AED
with a complementary mechanism of action, such
as levetiracetam (which binds to synaptic vesicle
proteins) or valproate (which is a GABAergic en-
hancer and has activity at the sodium channel).[12]
Conversely, the combination of lacosamide with
various agents that act on sodium channels (e.g.
benzodiazepine, carbamazepine, ethosuximide,
lamotrigine, oxcarbazepine, phenytoin, pheno-
barbital, topiramate, or zonisamide) appeared to
be less efficacious in this population.Moreover, it
has been suggested that the association of laco-
samide with other sodium channel-acting AEDs
can induce neurotoxicity.[12] Interestingly, the
proportion of patients who used co-AEDs was
greater in groups A and B (i.e. patients with a
favorable response to lacosamide therapy), al-
though it should be noted that this study was not
powered to make such comparisons.
We did not observe any relationship between
the response to lacosamide therapy and epileptic
syndrome. However, two patients with Lennox-
Gastaut syndrome reported a focal seizure reduc-
tion of >50%, which is in contrast to the worsening
of seizure control that has been previously re-
ported.[13] Moreover, we achieved great success in
one of the patients with continuous partial epilepsy
(Rasmussen’s syndrome), whose seizures appeared
to be controlled by lacosamide therapy. Indeed,
a similar outcome was observed in a 72-year-old
patient with refractory partial epileptic status
secondary to an ischemic lesion.[14]
Although the results of this study are encour-
aging and of great interest, the study had limi-
tations inherent to its design. The open-label
design of the study allowed for the potential that
the results might be affected by bias. The relatively
small number of patients limited the study power,
although this was a consequence of the 12-month
recruitment period. Another limitation of the
current study was the mixed patient population.
Patients with a variety of medication-resistant seiz-
ures were enrolled in the trial, including those with
symptomatic generalized epilepsy syndromes and
those with partial epilepsies. Because of the vari-
ety of underlying etiologies in this population, the
results may not be generalizable across all types of
pediatric patients.
Lacosamide appeared to be generally well
tolerated in this population. We did not observe a
dose-dependent relationship between lacosamide
therapy and the development of adverse effects.
Indeed, the patient who received the highest laco-
samide dose (20mg/kg/day) did not experience any
Table X. Concomitant antiepileptic drugs used with lacosamide in
patients with an increase in seizure frequency (group E; N =5)








co-AED = concomitant antiepileptic drug.
Table IX. Etiology and types of seizure in patients with no change in
seizure frequency (group D; N = 39)









S+C + 2aG 6
2aG 8
Presumably symptomatic C 2
2aG 3
C +2aG 3
2aG= secondarily generalized seizure; C = complex focal seizure;
S= simple focal seizure.
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adverse effects. Moreover, a very large dose of la-
cosamide, used in a suicide attempt, did not result
in death or permanent injury; complete physical
recoverywas achieved after several days.[15] Plasma
drug levels were not determined in our study,
although determination of saliva drug concen-
trations is a new alternative that may provide a
more objective method of analysis in the near fu-
ture.[16] As a consequence, this may enable a more
rational method of adjusting lacosamide doses.
The literature suggests that adverse effects
associated with lacosamide therapy are generally
mild-to-moderate in severity at doses of up to
600mg/day.[3,4,6] Although adverse effects were
observed in 30% of patients in our study, these
effects led to drug withdrawal in only 10% of the
overall study population. Additionally, the series
by Gavatha et al.[10] reported a similar incidence
of adverse effects (33%). In the study by Chez
et al.,[9] adverse effects were observed in 8.6% of
cases, which is a slightly lower rate, but lower
doses were also used. However, there continues
to be doubt concerning the hypothetical rela-
tionship between adverse effects and dose, which
we were unable to confirm either way.
The marked instability, difficulty walking, and
blurred vision that were observed here in ten
patients have also been reported previously in a
series of adult patients.[17] In five of our cases,
symptom intensity remained unchanged, despite
an immediate dose decrease, which eventually led
to suspension of treatment. Furthermore, these
symptoms differed significantly between patients,
which prevented determination of a convincing
pathophysiological explanation, or the relation-
ship between these symptoms and the use of other

























Fig. 1. Pattern of the treatment response (change in seizure frequency) to lacosamide therapy in children aged <16 years with refractory
epilepsy: Group A, seizure suppression; group B, >75% reduction in seizure frequency; group C, >50% to 75% reduction in seizure frequency;
group D, no change in seizure frequency; group E, increase in seizure frequency. The mean – standard deviation lacosamide doses
(mg/kg/day) were: group A, 6.97 – 2.15mg/kg/day; group B, 6.40 – 2.48mg/kg/day; group C, 6.63 – 2.33mg/kg/day; group D, 7.26 –2.62
mg/kg/day; group E, 6.16 – 0.52mg/kg/day.
Table XI. Etiology and types of seizure in patients with an increase
in seizure frequency (group E; N = 5)




Presumably symptomatic S 1
2aG 1
2aG= secondarily generalized seizure; C = complex focal seizure;
S= simple focal seizure.
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is required in randomized, controlled trials to
fully elucidate any causal factors in this patient
population.
No cardiovascular effects were observed in our
patients. In contrast, lacosamide has been asso-
ciated with atrial flutter/atrial fibrillation at doses
of 600mg/day or above in adults with epilepsy.[5]
Furthermore, we did not observe any alterations
in conventional laboratory tests or significant
changes in EEG records. However, we did not
have the opportunity to assess favorable effects
of lacosamide on photoparoxysmal responses,
which have recently been reported.[18]
Conclusion
In summary, lacosamide appears to be an ef-
fective and generally well tolerated AED in chil-
dren and adolescents with pharmaco-resistant
focal epileptic seizures. However, the instability,
accompanied by difficulty walking and blurred
vision, that was observed in ten patients requires
further investigation. On the basis of these re-
sults, we recommend an initial dose of
1–2mg/kg/day in children, followed by gradual
uptitration every 4–7 days, according to toler-
ability, until a mean dose of 6–9mg/kg/day is
achieved; the drug can be administered twice
daily (i.e. once every 12 hours). Although care
must be taken with concomitant use of AEDs
that act on sodium channels, adjunctive therapy
with lacosamide (a non-traditional sodium-
channel blocking AED) significantly reduced
seizure frequency regardless of co-administration
of traditional sodium-channel blockers in this
open-label trial.[19] Randomized controlled trials
of lacosamide are needed to confirm and validate
the efficacy and safety results observed here in
this pediatric population.
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Appendix: Lacosamide Spanish Study
Group Members
Dr. Alarco´n-Martı´nez (Hospital Universitario
Virgen de la Arrixaca, Murcia); Dr. Arrabal-
Ferna´ndez (Hospital Universitario Virgen de las
Nieves, Granada); Dr. Cabrera-Lo´pez (Hospital
Universitario Materno-Infantil, Las Palmas de
Gran Canaria, Canary Islands): Dr. Camino-
Leo´n (Hospital Universitario Reina Sofı´a, Cor-
doba); Dr. Campistol-Plana (Hospital Uni-
versitario San Juan de Dios, Barcelona); Dr.
Campos-Castello (Hospital Clı´nico San Carlos,
Madrid); Dr. Casas-Ferna´ndez (Hospital Uni-
versitario Virgen de la Arrixaca, Murcia); Dr.
Domingo Jime´nez (Hospital Universitario Virgen
de la Arrixaca, Murcia); Dr. Duque-Ferna´ndez
(Hospital Universitario Virgen de La Candelaria,
Santa Cruz de Tenerife); Dr. Eiris-Pun˜al (Hospi-
tal Clı´nico Universitario, Santiago de Compos-
tela); Dr. Garcı´a-Pen˜as (Hospital Universitario
Marque´s de Valdecilla, Santander); Dr. Herranz-
Ferna´ndez (Universidad de Cantabria, Santand-
er); Dr. Iba´n˜ez-Mico´ (Hospital Universitario
Virgen de la Arrixaca, Murcia); Dr. Jover-Cerda
(Hospital General de Elda, Alicante); Dr. Lara-
Table XII. Reasons for discontinuation of lacosamide (N =13)













Therapeutic inefficacy with no adverse effects 3
a Some patients experienced more than one adverse effect.
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Herguedas (Hospital Universitario Puerta de
Hierro-Majadahonda, Madrid); Dr. Lo´pez-
Lafuente (Hospital San Pedro de Alca´ntara,
Ca´ceres); Dr. Madruga-Garrido (Hospital Uni-
versitario Virgen del Rocı´o, Seville);Dr. Martı´nez-
Bermejo (Hospital Universitario La Paz, Madrid);
Dr. Martı´nez-Salcedo (Hospital Universitario
Virgen de la Arrixaca, Murcia); Dr. Puche-Mira
(Hospital Universitario Virgen de la Arrixaca,
Murcia); Dr. Rolda´n-Aparicio (Hospital Uni-
versitario Virgen de las Nieves, Granada);
Dr. Rufo-Campos (Instituto Hispalense de Pe-
diatrı´a, Seville); Dr. Santos-Borbujo (Hospital
Clı´nico Universitario, Salamanca); Dr. Smeyers-
Dura´ (Hospital Universitario La Fe, Valencia);
Dr. Teva-Gala´n (Hospital General de Elda,
Alicante); Dr. Valera-Pa´rraga (Hospital Uni-
versitario Virgen de la Arrixaca, Murcia).
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